Abstract: Use of trazodone for preparing pharmaceutical compositions of use in the prevention of infarction or acute cerebral ischaemia.Controlled-release pharmaceutical compositions which, in vitro, release from 1 to 20 mg/h of trazodone base.

Abstract: The invention herein is directed to a method of increasing the linear growth rate of hair by administering gelatin over a long period of time.

Abstract: It was discovered that bendazac, or (1-phenylmethyl-1H-indazol -3-yl)oxy acetic acid, when administered in a form suitable to obtain therapeutic tissue concentrations, determine an improvement in retinitis pigmentosa. The lysine salt of bendazac is well adapted for this use owing to its good oral absorption.

Abstract: It was discovered that bendazac, or [(1-benzyl-1H-indazol-3-yl)oxy] acetic acid, when administered in a form suitable to obtain therapeutic tissue concentrations, determines a regression of cataract. It was demonstrated in particular, that the lysine salt of bendazac is well adapted for this use since it produces adequate tissue concentrations following both oral administration and topical application on the eye. The chemical and physical characteristics of this bendazac salt are described here together with the preparation techniques.

Abstract: Novel compounds selected from the group consisting of 2-[3-[4-(3-chloro-4-fluorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3 -a]pyridine-3(2H)-one (I) and from its non-toxic pharmaceutically acceptable salts possess analgesic, anti-convulsant and anti-depressant activities.

Abstract: A new salt of [(1-benzyl-1H-indazol-3-yl)oxy] acetic acid (or bendazac) with L. lysine.Following oral administrations of this compound in man, the concentrations of bendazac found in the blood are higher than those obtained after administration of bendazac as such.This discovery extends the therapeutic use of bendazac. In fact, whereas up to now bendazac could only be used topically, the L. lysine salt of bendazac makes it possible to perform therapeutic treatments with the oral route of administration as an agent with a normalizing effect on blood lipids.

Abstract: Compounds of the general formula: ##STR1## in which alk and alk' represent the bivalent radicals; aliphatic alkyl chains; and R and R' represent the alkyl, halogen, hydrogen, alkyloxy, --OH, --CF.sub.3 or --SCH.sub.3 radicals. The compounds of the formula I are, effective as antiglaucomic, antipsychotic agents and also as additive agents in the withdrawal treatment of various addictive conditions. Methods for their preparation are also disclosed.

Abstract: Compounds of the general formula: ##STR1## in which alk and alk' represent the bivalent radicals: aliphatic alkyl chains; and R and R' represent the alkyl, halogen, hydrogen, alkyloxy, --OH, --CF.sub.3 or --SCH.sub.3 radicals. The compounds of the formula I are effective as antiglaucomic, antipsychotic and also as additive agents in the withdrawal treatment of various addictive conditions. Methods for their preparation are also disclosed.

Abstract: Compounds of the general formula: ##STR1## in which alk and alk' represent the bivalent radicals aliphatic alkyl chains; and R and R' represents the alkyl, halogen, hydrogen, alkyloxy, --OH, --CF.sub.3 or --SCH.sub.3 radicals. The compounds of the formula I are, effective as antiglaucomic, antipsychotic and also as additive agents in the withdrawal treatment of various addictive conditions. Methods for their preparation are also disclosed.

Abstract: This invention relates to the use of substituted 1-benzyl-1H-indazole-3-carboxylic acids to interrupt pregnancy. These compounds are described in the U.S. Pat. No. 3,895,026 assigned to the same assignee of the present patent application.

Abstract: Compound belonging to the class of 2-benzyl-3-(3-dimethylaminopropylthio)-2H-indazole, its sulfoxide and its sulfone and their pharmacologically acceptable salts, and process for obtaining such compounds having an antiinflammatory action in the common pathological conditions.

Abstract: Compounds of the general formula: ##STR1## in which alk and alk' represent the bivalent radicals; aliphatic alkyl chains; and R and R' represent the alkyl, halogen, hydrogen, alkyloxy, --OH, --CF.sub.3 or --SCH.sub.3 radicals. Said compounds of the formula I are effective and useful as antiglaucomic and antipsychotic agents and also as additive agents in the withdrawal treatment of various addictive conditions. Methods for their preparation are also disclosed.

Abstract: Treatment of tremors in Parkinsonism and in other extrapyramidal syndromes by administering an amount of trazodone of the formula ##STR1## AND OR OF ETOPERIDONE OF THE FORMULA: ##STR2## in the range of about 25 mg. to 100 mg. three times a day.

Abstract: S-Triazolo-[4,3-a]-pyridine derivatives and their nontoxic salts have been found to have pharmaceutical activity in the treatment of individuals suffering from the acute phases of the organic cerebral syndrome (stroke).

Abstract: This invention provides guaiacol p-isobutyl hydratropate as a new compound for use in human therapy as an analgesic, anti-inflammatory, antipyretic, antiseptic and expectorating agent.

Abstract: Treatment of tremors in Parkinsonism and in other extrapyramidal syndromes by administering an amount of trazodone of the formula ##STR1## AND OF ETOPERIDONE OF THE FORMULA: ##STR2## IN THE RANGE OF ABOUT 25 MG. TO 100 MG. THREE TIMES A DAY.

Abstract: A combination of trazodone or etoperidone with L-DOPA is used in the treatment of Parkinsonism by oral administration to a patient.